DMKJ
David M. Knott Jr Portfolio holdings
AUM
$221M
This Quarter Return
-12.56%
1 Year Return
+22.52%
3 Year Return
+148.91%
5 Year Return
–
10 Year Return
–
AUM
$212M
AUM Growth
+$212M
(-23%)
Cap. Flow
-$15.8M
Cap. Flow
% of AUM
-7.47%
Top 10 Holdings %
Top 10 Hldgs %
72.97%
Holding
103
New
14
Increased
10
Reduced
14
Closed
19
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$1.74M |
| 2 |
Myriad Genetics
MYGN
|
$1.42M |
| 3 |
Cogent Biosciences
COGT
|
$1.28M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$1.27M |
| 5 |
Bristol-Myers Squibb
BMY
|
$1.16M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$4.53M |
| 2 |
Calumet Specialty Products
CLMT
|
$4.49M |
| 3 |
Invesco AAA CLO Floating Rate Note ETF
ICLO
|
$3.34M |
| 4 |
Janus Henderson AAA CLO ETF
JAAA
|
$1.96M |
| 5 |
Viking Therapeutics
VKTX
|
$1.57M |
Sector Composition
| 1 | Healthcare | 33.25% |
| 2 | Materials | 20.41% |
| 3 | Financials | 19.12% |
| 4 | Communication Services | 8.29% |
| 5 | Industrials | 1.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Calumet Specialty Products
CLMT
$1.41B
| $41.8M | 19.73% | 3,297,194 -354,167 | -10% | -$4.49M |
|
2
Apollo Global Management
APO
$77.9B
| $30.8M | 14.54% | 225,000 | – | – |
|
|
3
Janus Henderson AAA CLO ETF
JAAA
$24.9B
| $28M | 13.2% | 551,763 -38,634 | -7% | -$1.96M |
|
4
Alphabet (Google) Class C
GOOG
$2.58T
| $17.5M | 8.27% | 112,220 | – | – |
|
5
DocGo
DCGO
$153M
| $8.11M | 3.82% | 3,070,850 | – | – |
|
6
Pfizer
PFE
$141B
| $6.45M | 3.04% | 254,537 | – | – |
|
7
Xeris Biopharma Holdings
XERS
$1.26B
| $6.09M | 2.88% | 1,110,000 +110,000 | +11% | +$604K |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $5.59M | 2.64% | 88,000 -71,300 | -45% | -$4.53M |
|
9
JPMorgan Chase
JPM
$829B
| $5.15M | 2.43% | 20,985 | – | – |
|
10
Catalyst Pharmaceutical
CPRX
$2.52B
| $5.14M | 2.43% | 212,000 +2,000 | +1% | +$48.5K |
|
11
Travere Therapeutics
TVTX
$1.56B
| $4.09M | 1.93% | 228,000 | – | – |
|
12
Protagonist Therapeutics
PTGX
$3.67B
| $3.68M | 1.73% | 76,000 +23,632 | +45% | +$1.14M |
|
13
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.45M | 1.63% | 460,000 +20,000 | +5% | +$150K |
|
|
AVDL
14
Avadel Pharmaceuticals
AVDL
$1.43B
| $3.34M | 1.57% | 426,000 +79,096 | +23% | +$619K |
|
|
ESGR
15
DELISTED
Enstar Group
ESGR
| $2.49M | 1.18% | 7,500 | – | – |
|
16
Ardelyx
ARDX
$1.53B
| $2.42M | 1.14% | 493,807 -118,463 | -19% | -$582K |
|
17
OmniAb
OABI
$230M
| $2.36M | 1.11% | 982,336 -112,169 | -10% | -$269K |
|
18
CSX Corp
CSX
$60.6B
| $2.06M | 0.97% | 70,000 | – | – |
|
19
AllianceBernstein
AB
$4.38B
| $1.84M | 0.87% | 48,000 | – | – |
|
|
20
Invesco AAA CLO Floating Rate Note ETF
ICLO
$344M
| $1.8M | 0.85% | 70,502 -130,985 | -65% | -$3.34M |
|
|
21
Ultragenyx Pharmaceutical
RARE
$2.89B
| $1.74M | 0.82% | +48,000 | New | +$1.74M |
|
22
Syndax Pharmaceuticals
SNDX
$1.41B
| $1.57M | 0.74% | 128,000 | – | – |
|
|
23
Myriad Genetics
MYGN
$593M
| $1.42M | 0.67% | +160,000 | New | +$1.42M |
|
|
24
Cogent Biosciences
COGT
$1.69B
| $1.28M | 0.6% | +213,302 | New | +$1.28M |
|
25
Panagram BBB-B CLO ETF
CLOZ
$846M
| $1.27M | 0.6% | 47,807 | – | – |
|